Prevalence of venous thromboembolism in patients with secondary polycythemia

Clinical and Applied Thrombosis/Hemostasis

Volumn 19, Issue 4, 2013, Pages 363-366

  Nadeem, Omar ^a   Gui, Jiang ^b   Ornstein, Deborah L ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

obesity; phlebotomy; polycythemia; venous thromboembolism

Indexed keywords

ADULT; AGED; ARTICLE; BODY MASS; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; ERYTHROCYTOSIS; FEMALE; HEMATOCRIT; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; VENOUS THROMBOEMBOLISM;

OBESITY; PHLEBOTOMY; POLYCYTHEMIA; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; HUMANS; MIDDLE AGED; NEW HAMPSHIRE; POLYCYTHEMIA; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84879992393     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029612460425     Document Type: Article

References (17)

1. Gruppo Italiano Studio Policitemia. Ann Intern Med. 1995 ; 123 (9). 656-664
2. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol. 1986 ; 23 (2). 132-143
3. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004 ; 350 (2). 114-124
4. Di Nisio M, Barbui T, Di Gennaro L, et al. The haematocrit and platelet target in polycythemia vera. Br J Haematol. 2007 ; 136 (2). 249-259
5. Wehmeier A, Sudhoff T, Meierkord F. Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders. Semin Thromb Hemost. 1997 ; 23 (4). 391-402
6. Panova-Noeva M, Marchetti M, Spronk HM, et al. Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera. Am J Hematol. 2011 ; 86 (4). 337-342
7. Falanga A, Barbui T, Rickles FR. Hypercoagulability and tissue factor gene upregulation in hematologic malignancies. Semin Thromb Hemost. 2008 ; 34 (2). 204-210
8. Falanga A, Marchetti M, Evangelista V, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood. 2000 ; 96 (13). 4261-4266
9. Kornberg A, Rahimi-Levene N, Yona R, Mor A, Rachmilewitz EA. Enhanced generation of monocyte tissue factor and increased plasma prothrombin fragment 1 + 2 levels in patients with polycythemia vera: mechanism of activation of blood coagulation. Am J Hematol. 1997 ; 56 (1). 5-11
10. Marchetti M, Castoldi E, Spronk HM, et al. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood. 2008 ; 112 (10). 4061-4068
11. Posan E, Ujj G, Kiss A, Telek B, Rak K, Udvardy M. Reduced in vitro clot lysis and release of more active platelet PAI-1 in polycythemia vera and essential thrombocythemia. Thromb Res. 1998 ; 90 (2). 51-56
12. Barbui T, Carobbio A, Rambaldi A, Finazzi G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?. Blood. 2009 ; 114 (4). 759-763
13. Carobbio A, Finazzi G, Antonioli E, et al. JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. Exp Hematol. 2009 ; 37 (9). 1016-1021
14. Landolfi R, Di Gennaro L. Prevention of thrombosis in polycythemia vera and essential thrombocythemia. Haematologica. 2008 ; 93 (3). 331-335
15. Landolfi R, Di Gennaro L, Barbui T, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood. 2007 ; 109 (6). 2446-2452
16. Landolfi R, Di Gennaro L, Falanga A. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia. 2008 ; 22 (11). 2020-2028
17. Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2012 ; 87 (3). 284-293